At the dawn of the social media era, Belle Gibson became a pioneering wellness influencer - telling the world how she beat cancer with an alternative diet. Her bestselling cookbook and online app provided her success, respect, and a connection to the cancer-battling influencer she admired the most. But a curious journalist with a sick wife began asking questions that even those closest to Belle began to wonder. Was the online star faking her cancer and fooling the world? Kaitlyn Dever stars in the Netflix hit series Apple Cider Vinegar . Inspired by true events, the dramatized story follows Belle’s journey from self-styled wellness thought leader to disgraced con artist. It also explores themes of hope and acceptance - and how far we’ll go to maintain it. In this episode of You Can't Make This Up, host Rebecca Lavoie interviews executive producer Samantha Strauss. SPOILER ALERT! If you haven't watched Apple Cider Vinegar yet, make sure to add it to your watch-list before listening on. Listen to more from Netflix Podcasts .…
พอดคาสต์ที่ควรค่าแก่การฟัง
สปอนเซอร์
Broadcasting the latest developments in GU cancer Hosted by Brian Rini and Tom Powles Brian Rini MD is Chief of Clinical Trials, Professor of Cancer Research and Professor of Medicine (Hematology/Oncology), Vanderbilt-Ingram Cancer Centre Tom Powles is Director of Barts Cancer Centre, St Bartholomews Hospital and Professor or Genitourinary oncology, Queen Mary University of London
…
continue reading
Toni Choueiri discusses the updated data from different cohorts of this novel HIF inhibitor.
…
continue reading
Vincent Xu discusses this emerging RCC biomarker and data from the Checkmate 214 trial
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 390: ASCO GU 2025 - Pembro-based Doublets in Refractory RCC and COSMIC-313 OS Update
30:03
Laurence Albiges joins the show to discuss novel combos in refractory RCC and an update of the Ipi/Nivo/Cabo COSMIC OS data
…
continue reading
Gopa Iyer from MSKCC joins the show to discuss his initial results from this phase 2 trial.
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 387: ASCO GU 2025 -Neoadjuvant Disitamab Vedotin + Toripalimab in HER2+ MIBC: updated efficacy and safety results
27:07
Xinan Sheng. M.D., Professor in the Department of Genitourinary Oncology at Peking University Cancer Hospital &institute in Beijing, China joins us to discuss the update of this trial and impressive pCR rates.
…
continue reading
Matt Galsky joins the show to discuss pCR in NIAGARA and clinical implications.
…
continue reading
Tanya Dorff from City of Hope joins us to discuss clinical implications of these data and also comment on TALAPRO-2
…
continue reading
Neeraj Aggarwal joins Tom and Brian for an in-depth look at these important data
…
continue reading
Silke Gillessen joins Brian and Tom and they discuss what to look forward to in prostate, bladder and RCC at ASCO GU 2025.
…
continue reading
David Braun joins the show to discuss his Nature paper on a personalized RCC vaccine
…
continue reading
残念ながらNegative StudyとなったTROPICs-04についてUromigosJapanの3人が忖度なしに、その原因や理由について考察をします!!
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 381: Molecular heterogeneity in urothelial carcinoma and determinants of clinical benefit to PD-L1 blockade
40:05
Romain Banchereau joins the show to discuss and debate this Cancer Cell paper on molecular subtypes in urothelial cancer and implications for checkpoint blockade.
…
continue reading
Shankar Siva joins the show to discuss the emerging role of stereotactic body radiotherapy (SBRT) in primary and metastatic RCC tumors.
…
continue reading
3人による2024年のGU oncoloyのレビューを切れ味鋭く解説しています。乞うご期待!
…
continue reading
Tanya Dorff from City of Hope joins Brian and Tom to review what to expect throughout 2025 and beyond in terms of clinically impactful data in prostate, renal and bladder cancer
…
continue reading
David McDermott (and his dog, Finn) join the show to review the top data from 2024 in RCC
…
continue reading
Matt Galsky joins Brian and Tom to discuss the most impactful data in bladder cancer form the past year.
…
continue reading
Silke Gilleson gives Tom and Brian 3 'gifts': Thomas Zilli (Radiation Oncology), Jochen Walz (Urology) and Ken Hermann (Nuclear Medicine) who discuss the 2024 prostate highlights from each of their unique perspectives.
…
continue reading
Jim Brugarolas joins to discuss his talk from IKCS 2024 and the board topic of resistance to HIF inhibitors.
…
continue reading
JSCO2024で発表されたKEYNOTE-564東アジア人OSデータとANNAR biomarker studyの解説とディスカッションです
…
continue reading
Dan Suzman from FDA joins us to discuss the Accelerated Approval process, requirements, successes and challenges.
…
continue reading
Jonathan Rosenberg joins Brian and Tom to discuss this important phase 3 trial and efficacy and toxicity signals.
…
continue reading
Jacob Kather joins Brian and Tom to discuss emerging AI applications in Oncology
…
continue reading
Bishoy joins us to discuss his work on extrachromosomal DNA in bladder cancer from his latest Nature publication
…
continue reading
Andrew Smith from St. Jude's joins us to discuss the emerging field of radiomics and shares his hopes and skepticism
…
continue reading
Chuck Ryan from MSKCC joins to talk about various aspects of AR inhibition in prostate cancer and relative benefits and risks.
…
continue reading
Chris Sweeney and Rob Jones join Brian and Tom to discuss the relative merits of different ARPIs in prostate cancer.
…
continue reading
Episode 365: Silke Gillessen and Betrand Tombal join the show to discuss the APCCC meeting and recent publication.
…
continue reading
腎がんの最新の話題〜IO rechallengeと乳頭型腎がんの治療戦略〜
…
continue reading
前立腺がんの最新の話題〜T cell directed therapyとradioligands〜
…
continue reading
膀胱がんの最新の話題〜周術期薬物療法とADC〜
…
continue reading
Betrand Tombal joins Brian and Tom to discuss the historic and current data for AR inhibition with monotherapy with AR blockers.
…
continue reading
Christopher Cutie from J&J joins the show to discuss the SUNRISE bladder program with the gemcitabine-eluting pretzel across several NMIBC and MIBC states.
…
continue reading
The RCC panel at Uromigos Live 2024 discusses and debates this topic.
…
continue reading
Eneste podcast cubrimos los temas de cáncer urotelial discutidos por los Uromigos. El impacto del estudio NIAGARA en utiliar quimio más inmunoterapia enneadyuvancia de Ca urotelial músculo invasor, el uso de pembrolizumab adyuvante después de los datos del estudio AMBASSADOR y la búsqueda de biomarcadores.…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 357: #UromigosLive24 - Peri-operative Therapy in Bladder Cancer
1:03:10
1:03:10
ลิสต์เล่นในภายหลัง
ลิสต์เล่นในภายหลัง
ลิสต์
ถูกใจ
ที่ถูกใจแล้ว
1:03:10Tom leads a panel of Shilpa Gupta, Andrea Apolo, Kala Sridhar and Petros Grivas to discuss and debate this timely topic.
…
continue reading
Brian moderates the panel that discusses and debates TKI, vs Ipi/Nivo vs IO/TKI
…
continue reading
The Uromigos Live 2024 panel discusses recent radioligand data including PEACE-3
…
continue reading
Brian hosts a panel at Uromigos Live 2024 in Nashville with Michael Morris, Tanya Dorff and Karen Autio
…
continue reading
Tom moderates a live panel of Kala Sridhar, Shilpa Gupta, Andrea Apolo and Petros Grivas on the emerging ADC data in bladder cancer
…
continue reading
Tom and Brian finish discussing ESMO 2024 highlights. Even without a guest Tom still interrupts a lot.
…
continue reading
Silke joins us to discuss ESMO 2024 highlights, then the birds start singing....
…
continue reading
Fresh of the Presidential session address, Tom discusses his data with Petros commenting.
…
continue reading
Uromigos Japan with Yuji, Hiroshi and Nobu is formed and discuss Hiroshi's ESMO data.
…
continue reading
Arun Azad describes this randomised phase II study of sequential 177Lu-PSMA-617 and docetaxel vs. docetaxel in mHSPC
…
continue reading
Matt Galsky describes his ESMO 2024 abstract of disitimab vedotiin + pembrlizumab in bladder cancer
…
continue reading
Silke Gillessen joins us to discuss her Presidential session from ESMO 2024
…
continue reading
Lothar Bergmann describes this investigator-initiated trial of Ipi/Nivo vs SOC in Non-clear Cell RCC
…
continue reading
Brad McGregor joins Brian and Tom to discuss a new HIF inhibitor, NKT2152, and preliminary data in RCC
…
continue reading
Katy Beckermann discusses the TiNivo-2 study presented at ESMO 2024.
…
continue reading